Device Trial Radar · NCT04882592
Noninvasive Spinal Neuromodulation Enables Locomotor Recovery in Individuals With Cerebral Palsy
Last checked: Nov 20, 2026Latest source record: Apr 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
50
Planned (sponsor's estimate)
Start
May 15, 2021
Primary completion
Dec 1, 2023
Study completion Dec 1, 2024
Sponsor
- Lead sponsor
- SpineX Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- May 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Crossover
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 2 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Assessing the effects of noninvasive spinal cord neuromodulation on improving function in individuals with cerebral palsy
Conditions
- Cerebral Palsy
Interventions
SCiPDevice
Noninvasive spinal cord neuromodulator
Primary outcomes
What the sponsor says the trial is designed to measure.
- Stepping overground or on a treadmillTime frame: 3 months
- Gross Motor Functional Measure (GMFM)Time frame: 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
SpineX
Los Angeles, California · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.